Hormonal acne

What it is

Hormonal acne is androgen-driven acne vulgaris that affects an estimated 40–55% of adult women aged 20–29 and roughly 26% of women in their 40s, making it one of the most common dermatological complaints in adult female patients. Also called adult female acne (AFA) or androgen-mediated acne, the condition is defined by inflammatory lesions — typically deep papules, nodules, and cysts — concentrated along the jawline, chin, and lower cheeks, with flares that track predictably with the menstrual cycle, pregnancy, perimenopause, or conditions such as polycystic ovary syndrome (PCOS).

Unlike the diffuse comedonal acne common in adolescence, hormonal acne in adults tends to be cyclical and inflammatory rather than primarily blackhead-driven. In Canada, it is a frequent reason for referral to dermatology and a recognized indication for hormonal therapy under both dermatology and primary-care guidelines.

Causes and mechanism

The central driver is androgen activity at the sebaceous gland. Androgens — primarily testosterone and its more potent derivative dihydrotestosterone (DHT) — bind to receptors in sebocytes (sebum-producing cells), triggering excess sebum production. That excess sebum, combined with abnormal follicular keratinization and colonization by Cutibacterium acnes (formerly Propionibacterium acnes), creates the inflammatory environment that produces acne lesions.

Several hormonal states raise androgen activity enough to provoke or worsen acne:

Trigger	Mechanism	Typical timing
Luteal phase of menstrual cycle	Progesterone rises; estrogen drops, reducing sebum suppression	7–10 days before period
PCOS	Elevated free testosterone + insulin resistance amplify androgen signalling	Persistent, often severe
Perimenopause	Estrogen declines faster than androgens, shifting the ratio	Late 30s–50s
Pregnancy (first trimester)	Progesterone surge increases sebum output	Weeks 6–12
Androgenic progestin-containing OCs	Some progestins (e.g., levonorgestrel, norgestrel) have androgenic activity	Onset after starting OC

Importantly, many women with hormonal acne have serum androgen levels within the normal laboratory range. The issue is often heightened sebaceous gland sensitivity to normal androgen concentrations, not frank hyperandrogenism. This is why hormonal therapies can be effective even when bloodwork appears unremarkable.

Symptoms and diagnosis

Clinically, hormonal acne presents as:

• Deep, tender papules and nodules along the lower face (jawline, chin, perioral area)
• Flares that worsen in the week before menstruation
• Resistance to topical retinoids or antibiotics used alone
• Scarring and post-inflammatory hyperpigmentation, which can be more pronounced in darker skin tones

Diagnosis is clinical. A dermatologist or family physician will assess lesion distribution, menstrual history, and any signs of hyperandrogenism (hirsutism, irregular cycles, scalp hair thinning). If PCOS or another endocrine disorder is suspected, bloodwork may include free and total testosterone, DHEA-S, LH/FSH ratio, fasting insulin, and prolactin. In Canada, these panels are available through LifeLabs and Dynacare and are generally covered under provincial health plans when ordered for a clinical indication.

Treatment options

Treatment is typically stepwise and may combine topical and systemic approaches:

Topical therapies — Retinoids (tretinoin, adapalene) and topical antibiotics (clindamycin) remain first-line adjuncts. They address the follicular and bacterial components but do not correct the underlying hormonal driver.

Combined oral contraceptives (COCs) — Three COC formulations are approved by Health Canada specifically for acne: norgestimate/ethinyl estradiol (Ortho Tri-Cyclen), norethindrone acetate/ethinyl estradiol (Estrostep), and drospirenone/ethinyl estradiol (Yaz). COCs work by suppressing ovarian androgen production and increasing sex hormone-binding globulin (SHBG), which binds free testosterone and reduces its availability to sebaceous glands.

Spironolactone — An aldosterone antagonist that also blocks androgen receptors in the skin. Used off-label for hormonal acne in Canada at doses of 50–200 mg/day, it is well-supported by clinical evidence and widely prescribed by Canadian dermatologists. It is not appropriate during pregnancy.

Oral isotretinoin — Reserved for severe, scarring, or treatment-resistant cases. Requires enrollment in the iPLEDGE program (or its Canadian equivalent monitoring protocols) due to teratogenicity.

Other options — Low-dose oral antibiotics (doxycycline, minocycline) are sometimes used short-term as a bridge, though antibiotic stewardship guidelines discourage long-term use. Topical clascoterone (a topical androgen receptor blocker) has shown efficacy in trials but as of 2024 has limited availability in Canada.

Canadian patients can access assessment and prescriptions for hormonal acne treatments through dermatologists, family physicians, and virtual-care platforms including Felix, Maple, Cleo, and Phoenix, though formulary coverage for spironolactone and COCs varies by province.

When to see a clinician in Canada

See a family physician or dermatologist if:

• Acne is leaving scars or persistent dark marks
• Breakouts are not responding after 8–12 weeks of over-the-counter treatment
• Flares are clearly tied to your menstrual cycle or a hormonal transition (perimenopause, stopping the pill)
• You have other signs of androgen excess: irregular periods, unwanted facial or body hair, or scalp thinning
• You are considering stopping a hormonal contraceptive and want to plan for potential acne rebound

Most provincial plans cover dermatology referrals, though wait times vary. Virtual dermatology services can shorten access time for straightforward hormonal acne cases.

Limitations and open questions

Research is still emerging on several fronts. The optimal dose and duration of spironolactone for hormonal acne has not been established by large randomized controlled trials, and most evidence comes from retrospective cohort studies. The role of diet — particularly high-glycaemic-index foods and dairy — in triggering hormonal acne flares is biologically plausible but not yet confirmed by high-quality evidence; Health Canada has not issued dietary guidance specific to acne. The long-term safety profile of low-dose spironolactone in premenopausal women is generally considered favourable, but data beyond five years of continuous use are limited. It is also unclear whether topical clascoterone will achieve broad formulary coverage in Canadian provinces, and no head-to-head Canadian trials comparing it to spironolactone exist. Finally, the mechanisms by which stress hormones (cortisol, adrenal androgens) amplify acne flares are not fully characterized, making stress-reduction a reasonable but evidence-light recommendation.